Actively Recruiting
Immune Spatial Features of Guselkumab Cutaneous Response
Led by University of California, San Francisco · Updated on 2023-08-28
10
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
J
Janssen Scientific Affairs, LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
CONDITIONS
Official Title
Immune Spatial Features of Guselkumab Cutaneous Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with a psoriasis scalp severity index (PSSI) of 12 or higher
You will not qualify if you...
- Taking systemic immunosuppressive drugs within the last 4 weeks
- Pregnant
- Severe immunodeficiency from genetic or infectious causes
- Active tuberculosis or other serious infections
- Active systemic cancer
- Breastfeeding
- Any condition that could affect patient safety or data quality as judged by the investigator
- Males trying to conceive
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California San Francisco
San Francisco, California, United States, 94115
Actively Recruiting
Research Team
J
Jeffrey Cheng, MD, PhD
CONTACT
R
Raymond Cho, MD,PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here